Rubius Therapeutics, Inc. (RUBY): Price and Financial Metrics
GET POWR RATINGS... FREE!
RUBY Stock Price Chart Interactive Chart >
RUBY Price/Volume Stats
| Current price | $1.19 | 52-week high | $29.06 |
| Prev. close | $1.06 | 52-week low | $0.90 |
| Day low | $1.04 | Volume | 580,200 |
| Day high | $1.19 | Avg. volume | 1,168,889 |
| 50-day MA | $2.71 | Dividend yield | N/A |
| 200-day MA | $10.36 | Market Cap | 107.35M |
Rubius Therapeutics, Inc. (RUBY) Company Bio
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Latest RUBY News From Around the Web
Below are the latest news stories about Rubius Therapeutics Inc that investors may wish to consider to help them evaluate RUBY as an investment opportunity.
INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANTInvaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. |
Rubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial ResultsCAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report fourth quarter and full year 2021 financial results on Friday, February 25, 2022, before market open. The company will not be hosting a teleconfe |
Rubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February 2022CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that the executive management team will present and host meetings with investors at the virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Con |
Rubius Therapeutics begins dosing in phase 1/2 trial of RTX-224 for solid tumorsRubius Therapeutics (RUBY) said the first patient was dosed in its phase 1/2 trial of RTX-224 to treat patients with certain relapsed/refractory or locally advanced solid tumors, |
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid TumorsCAMBRIDGE, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune disease, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of RTX-224 for the treatment of patients with certain relapsed/refractory or locally advance |
RUBY Price Returns
| 1-mo | -31.61% |
| 3-mo | -76.29% |
| 6-mo | -89.97% |
| 1-year | -95.13% |
| 3-year | -92.61% |
| 5-year | N/A |
| YTD | -87.71% |
| 2021 | 27.54% |
| 2020 | -20.11% |
| 2019 | -40.92% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...